Immunic reports reduced disability worsening in progressive multiple sclerosis trial

• click to rate

  Posted by Two Blokes Apr 30 - Filed in Stock - 0 views
  
  Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in patients with primary progressive multiple sclerosis (PPMS) compared to placebo. The study enrolled 467 patients with progressive multiple sclerosis (PMS), including subpopulations with PPMS and non-active secondary progressive multiple sclerosis.